These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14529361)

  • 1. The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.
    Allan SM; Pinteaux E
    Curr Drug Targets CNS Neurol Disord; 2003 Oct; 2(5):293-302. PubMed ID: 14529361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 1 in the brain: biology, pathology and therapeutic target.
    Rothwell NJ; Luheshi GN
    Trends Neurosci; 2000 Dec; 23(12):618-25. PubMed ID: 11137152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation in central nervous system injury.
    Allan SM; Rothwell NJ
    Philos Trans R Soc Lond B Biol Sci; 2003 Oct; 358(1438):1669-77. PubMed ID: 14561325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1 and inflammatory neurodegeneration.
    Simi A; Tsakiri N; Wang P; Rothwell NJ
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1122-6. PubMed ID: 17956293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connection between inflammatory processes and transmittor function-Modulatory effects of interleukin-1.
    Spulber S; Schultzberg M
    Prog Neurobiol; 2010 Feb; 90(2):256-62. PubMed ID: 19853010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting JNK3 for the treatment of neurodegenerative disorders.
    Resnick L; Fennell M
    Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1: a master regulator of neuroinflammation.
    Basu A; Krady JK; Levison SW
    J Neurosci Res; 2004 Oct; 78(2):151-6. PubMed ID: 15378607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-1 as a target in inflammation.
    Ito Y; Kaneko N; Iwasaki T; Morikawa S; Kaneko K; Masumoto J
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):206-11. PubMed ID: 26333726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegenerative disorders--4th annual SMi conference.
    Phillips T
    IDrugs; 2004 Aug; 7(8):721-4. PubMed ID: 15334302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain drug delivery systems for neurodegenerative disorders.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2388-402. PubMed ID: 23016644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches.
    Van Eldik LJ; Thompson WL; Ralay Ranaivo H; Behanna HA; Martin Watterson D
    Int Rev Neurobiol; 2007; 82():277-96. PubMed ID: 17678967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic strategy for Parkinson's and Alzheimer's disease.
    Esposito E; Cuzzocrea S
    Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6, a mental cytokine.
    Spooren A; Kolmus K; Laureys G; Clinckers R; De Keyser J; Haegeman G; Gerlo S
    Brain Res Rev; 2011 Jun; 67(1-2):157-83. PubMed ID: 21238488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Regulatory Role of IL-10 in Neurodegenerative Diseases.
    Porro C; Cianciulli A; Panaro MA
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32659950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the JNK pathway for therapeutic benefit in CNS disease.
    Bozyczko-Coyne D; Saporito MS; Hudkins RL
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):31-49. PubMed ID: 12769633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
    Bisogno T; Di Marzo V
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.